Recent advances in diabetes technology have transformed the clinical management of type 1 diabetes in children and adolescents. The integration of continuous glucose monitoring (CGM) and advanced hybrid closed-loop (AHCL) insulin delivery systems has enabled tighter glycemic control and greater treatment individualization. These developments are increasingly supported by emerging glucose control indicators, such as time in range (TIR) and glycemic variability, which provide more nuanced assessments of glucose control than HbA1c alone.
This Research Topic invites contributions that investigate how these tools and metrics can improve the clinical management of pediatric type 1 diabetes and reduce the risk of acute and chronic complications. Submissions focused on real-world outcomes, early risk markers, and longitudinal assessments of metabolic control are especially encouraged.
Topics of interest include:
• Long-term outcomes of AHCL and CGM use in pediatric type 1 diabetes
• Clinical utility of Time in Range, Time in Tight Range, and glycemic variability as predictors of complication risk
• Optimization strategies for insulin delivery technologies to improve metabolic control
• Associations between glycemic metrics and early signs of microvascular or metabolic complications
• Individualized treatment approaches informed by glycemic data and device performance
• Predictive factors for sustained glycemic improvement in pediatric cohorts
By focusing on measurable clinical outcomes and the prevention of complications, this Topic aims to bridge innovations in diabetes care with evidence-based practice in pediatric endocrinology.
Recent advances in diabetes technology have transformed the clinical management of type 1 diabetes in children and adolescents. The integration of continuous glucose monitoring (CGM) and advanced hybrid closed-loop (AHCL) insulin delivery systems has enabled tighter glycemic control and greater treatment individualization. These developments are increasingly supported by emerging glucose control indicators, such as time in range (TIR) and glycemic variability, which provide more nuanced assessments of glucose control than HbA1c alone.
This Research Topic invites contributions that investigate how these tools and metrics can improve the clinical management of pediatric type 1 diabetes and reduce the risk of acute and chronic complications. Submissions focused on real-world outcomes, early risk markers, and longitudinal assessments of metabolic control are especially encouraged.
Topics of interest include:
• Long-term outcomes of AHCL and CGM use in pediatric type 1 diabetes
• Clinical utility of Time in Range, Time in Tight Range, and glycemic variability as predictors of complication risk
• Optimization strategies for insulin delivery technologies to improve metabolic control
• Associations between glycemic metrics and early signs of microvascular or metabolic complications
• Individualized treatment approaches informed by glycemic data and device performance
• Predictive factors for sustained glycemic improvement in pediatric cohorts
By focusing on measurable clinical outcomes and the prevention of complications, this Topic aims to bridge innovations in diabetes care with evidence-based practice in pediatric endocrinology.